Condition: Cardiac Allograft Vasculopathy · Heart Transplant · Sponsor: Ottawa Heart Institute Research Corporation
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
This description comes directly from the study's public registry record.
Sharon Chih · 613-696-7000 · schih@ottawaheart.ca
Heather Ross · heather.ross@uhn.ca
Always discuss trial participation with your own doctor first.
| St.Pauls Hospital | Vancouver, British Columbia, Canada | Recruiting |
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Recruiting |
| Toronto General Hospital UHN | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04770012